SB1317
| CAS No. | 937270-47-8 | Cat. No. | BCP07033 |
| Name | SB1317 | ||
| Synonyms | TG02; SB 1317; TG 02; SB-1317; TG-02; | ||
| Formula | C23H24N4O | M. Wt | 372.46 |
| Description | TG02, also known as SB1317, is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs. TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis. In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and S | ||
| Related Products | 1204918-72-8（SB 1317） | ||
| Pathways | Angiogenesis/Protein Tyrosine Kinase Cell Cycle/DNA Damage Jak/Stat Pathway Wnt/Stem Cell Epigenetics | ||
| Targets | FLT3 JAK CDK | ||
Structure
Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.
For product details of different batches, please contact our Customer
- Service & Tech Support:orders@biochempartner.com
- Website:www.biochempartner.com
Products are for research use only and not for human use. We do not sell to patients.